糖皮质激素联合复方异丙托溴铵对慢阻肺急性加重期的治疗意义探析(1)

http://www.100md.com 2018年8月15日 《中国医学创新》 2018年第23期

     【摘要】 目的：研究糖皮質激素联合复方异丙托溴铵对慢性阻塞性肺疾病急性加重期(Acute exacerbation of chronic obstructive pulmonary disease，AECOPD)的治疗意义。方法：选取2015年4月-2016年10月本院收治的AECOPD患者60例。按照随机数字表法将其分为对照组(n=30)和观察组(n=30)。对照组接受布地奈德雾化吸入治疗，在此基础上，观察组加施复方异丙托溴铵雾化吸入治疗。比较两组治疗前后的血清炎症因子、凝血功能及免疫功能指标水平及治疗效果。结果：观察组总有效率为93.33%，高于对照组的76.67%，比较差异有统计学意义(字2=6.67，P=0.01)；治疗后，两组IFN-γ、hs-CRP、TNF-α、FIB、D-D水平均低于治疗前，且观察组均低于对照组，比较差异均有统计学意义(P<0.05)；治疗后，观察组CD4+、CD8+及CD4+/CD8+均高于治疗前及对照组，比较差异均有统计学意义(P<0.05)。结论：糖皮质激素联合复方异丙托溴铵治疗AECOPD疗效显著，能够有效调节患者免疫功能，并改善机体炎症状态以及凝血功能，值得临床推广。
, 百拇医药
    【关键词】 糖皮质激素； 复方异丙托溴铵； 慢性阻塞性肺疾病； 急性加重期

    Effect of Glucocorticoid Combined with Compound Ipratropium Bromide on Acute Exacerbation of Chronic Obstructive Pulmonary Disease/WANG Yi.//Medical Innovation of China，2018，15(23)：-106

    【Abstract】 Objective：To study the therapeutic effect of glucocorticoid combined with Compound Ipratropium Bromide on acute exacerbation of chronic obstructive pulmonary disease(AECOPD).
, 百拇医药
    Method：A total of 60 patients with AECOPD admitted to our hospital from April 2015 to October 2016 were selected.According to random number table method，they were divided into control group(n=30) and observation group(n=30).The control group received Budesonide atomization inhalation therapy.On this basis，the observation group was treated with Compound Ipratropium Bromide aerosol inhalation therapy.The serum inflammatory factors，coagulation function and immune function indicators before and after treatment，and treatment effects of the two groups were compared.Result：The total effective rate in the observation group was 93.33%，which was higher than 76.67% in the control group，the difference was statistically significant
, 百拇医药
    (字2=6.67，P=0.01).After treatment，the levels of IFN-γ，hs-CRP，TNF-α，FIB and D-D in the two groups were lower than those before treatment，and the observation group were lower than those the control group，the differences were statistically significant(P<0.05).After treatment，the CD4+，CD8+and CD4+/CD8+ of the observation group were higher than those before treatment and the control group，the differences were statistically significant(P<0.05).Conclusion：Glucocorticoid combined with Compound Ipratropium Bromide has significant curative effect in the treatment of AECOPD，it can effectively regulate the immune function of patients and improve the inflammatory state and coagulation function.It is worthy of clinical promotion.

    【Key words】 Glucocorticoid； Compound Ipratropium Bromide； Chronic obstructive pulmonary disease； Acute exacerbation, 百拇医药(王熠)

第 1 2 3 页 下一页

    百拇医药网 http://www.100md.com/html/paper/1674-4985/2018/23/27.htm